MNG1282
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.424
- ANGIOGENESIS+0.408
- G2M_CHECKPOINT+0.406
- PANCREAS_BETA_CELLS+0.328
- HEDGEHOG_SIGNALING+0.318
- OXIDATIVE_PHOSPHORYLATION+0.227
- MYC_TARGETS_V1+0.170
- MTORC1_SIGNALING+0.157
- MYC_TARGETS_V2+0.152
- GLYCOLYSIS+0.146
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.471
- INTERFERON_GAMMA_RESPONSE-0.436
- TGF_BETA_SIGNALING-0.332
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.326
- PEROXISOME-0.303
- HEME_METABOLISM-0.287
- ALLOGRAFT_REJECTION-0.281
- IL6_JAK_STAT3_SIGNALING-0.278
- IL2_STAT5_SIGNALING-0.239
- APOPTOSIS-0.233
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3082 | Med | Medulloblastoma | 0.827 |
| 2 | TCGA-GV-A3JZ-01A-11R-A21D-07 | — | — | 0.809 |
| 3 | MNG737 | — | — | 0.802 |
| 4 | SRR10900595 | — | — | 0.792 |
| 5 | MNG798 | — | — | 0.785 |
| 6 | AUR-AG0M-TTM1-A-2-1-R-A743-41 | — | A | 0.745 |
| 7 | 91648 | EPN | Supratentorial EPN | 0.744 |
| 8 | MNG142 | — | — | 0.743 |
| 9 | SRR5088864 | — | — | 0.742 |
| 10 | MNG592 | — | — | 0.734 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.424 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.408 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.406 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.328 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.318 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.227 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.170 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.157 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.152 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.146 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.138 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.107 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.102 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.037 | Idelalisib | — uncovered |
| COAGULATION | 0.036 | Binimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.026 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.010 | Inavolisib | — uncovered |